BioStem Technologies Announces $2.5 Million Private Placement Financing with its First Institutional Investor

May 22, 2026 | BioStem in the News

POMPANO BEACH, Fla., May 22, 2026 (GLOBE NEWSWIRE) — BioStem Technologies Inc.(OTC: BSEM), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced it has...

BioStem Technologies Announces Notice of Allowance for Four U.S. Design Patent Applications Covering Fenestrated Human Placental Allografts and One European Patent

May 10, 2026 | BioStem in the News

Pompano Beach, FL, May 20, 2026 (GLOBE NEWSWIRE) — BioStem Technologies®, a leading regenerative medicine company focused on developing and commercializing placental-derived biologics, today announced that the United States Patent and Trademark Office (USPTO)...

BioStem Technologies Reports First Quarter 2026 Financial Results

May 14, 2026 | BioStem in the News

POMPANO BEACH, Fla., May 14, 2026 (GLOBE NEWSWIRE) — BioStem Technologies, Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today reported financial...

BioStem Technologies to Present at the 16th Annual LD Micro Invitational

May 12, 2026 | BioStem in the News

POMPANO BEACH, Fla., May 12, 2026 (GLOBE NEWSWIRE) — BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced that...

BioStem Technologies to Host First Quarter 2026 Financial Results Conference Call on May 14, 2026

Apr 30, 2026 | BioStem in the News

POMPANO BEACH, Fla., April 30, 2026 (GLOBE NEWSWIRE) — BioStem Technologies, Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announces it...

BioStem Strengthens Leadership Team with Appointment of Katherine Gorrell as Chief Legal & Compliance Officer

Apr 30, 2026 | BioStem in the News

POMPANO BEACH, Fla., April 30, 2026 (GLOBE NEWSWIRE) — BioStem Technologies (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacturing and commercialization of perinatal tissue allograft products, today announced the...